To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Investigator
- Nikolaus McFarland
- Status
- Accepting Candidates
- Ages
- 40 Years - 75 Years
- Sexes
- All
Dr. McFarland is a member of the Norman Fixel Institute for Neurological Diseases and the Center for Translational Research in Neurodegenerative Disease (CTRND), which aims to bring the bench research closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and on identifying novel biomarkers for early detection and tracking of disease and therapeutic development. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label…
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in…
97 publications
2020
Movement disorders : official journal of the Movement Disorder Society
•2020
Journal of the neurological sciences
•2019
Clinical biomechanics (Bristol, Avon)
•2019
The Lancet. Digital health
•2019
NeuroImage
•